StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX - Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Friday.
Other equities research analysts also recently issued reports about the company. HC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Bank of America reaffirmed a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Robert W. Baird assumed coverage on shares of Catalyst Pharmaceuticals in a research note on Tuesday, February 4th. They set an "outperform" rating and a $28.00 price target on the stock. Finally, Truist Financial increased their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $32.50.
Get Our Latest Research Report on CPRX
Catalyst Pharmaceuticals Stock Down 1.0 %
NASDAQ CPRX traded down $0.22 during midday trading on Friday, hitting $22.10. The company had a trading volume of 988,851 shares, compared to its average volume of 1,278,072. The firm has a fifty day simple moving average of $22.26 and a two-hundred day simple moving average of $21.47. Catalyst Pharmaceuticals has a fifty-two week low of $14.47 and a fifty-two week high of $24.64. The stock has a market cap of $2.68 billion, a price-to-earnings ratio of 18.73, a P/E/G ratio of 3.31 and a beta of 0.80.
Insider Activity
In other news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 11.00% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Catalyst Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter worth $27,000. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $29,000. Farther Finance Advisors LLC lifted its position in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 1,495 shares in the last quarter. Larson Financial Group LLC grew its holdings in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 2,994 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at about $65,000. 79.22% of the stock is owned by institutional investors and hedge funds.
About Catalyst Pharmaceuticals
(
Get Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Read More
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
